Welcome to this week’s PharmaSignal Weekly Brief – Global Pharma Roundup. This week, we have seen significant movement in the M&A landscape, with major deals reshaping the biotech and rare disease sectors. Meanwhile, the FDA has been active in granting approvals and fast passes, potentially altering the competitive dynamics in several therapy areas. In the R&D space, promising trial results and strategic funding rounds have made headlines, while policy signals and market trends continue to shape the global pharma landscape. M&A and Strategic Deals BioMarin has acquired Amicus in a $4.8 billion deal, strengthening its rare disease portfolio and expanding…
Browsing: Weekly Digest
Weekly summary of the most important pharma and biotech updates curated by PharmaSignal.
In this week’s PharmaSignal Weekly Brief – Global Pharma Roundup, significant M&A activity, key regulatory approvals, and notable pipeline developments shaped the global pharma landscape. Meanwhile, pricing decisions and policy shifts continue to influence market dynamics and strategic positioning. M&A and Strategic Deals Johnson & Johnson’s acquisition of Halda Therapeutics for $3.05B expands its footprint in the metabolic disease space. Read more → Biogen’s partnership with Dayra aims to enhance its immunological disease portfolio, indicating a strategic focus on immune-mediated conditions. Read more → Regulatory and Approvals Otsuka secured FDA approval for Voyxact in kidney disease, marking a significant step…
In this week’s PharmaSignal Weekly Brief – Global Pharma Roundup, we see a flurry of M&A activity, key regulatory approvals, and significant pipeline developments. Meanwhile, the global pharma landscape is also being shaped by important market, pricing, and policy signals. M&A and Strategic Deals Johnson & Johnson’s acquisition of Halda Therapeutics for $3.05 billion marks a significant expansion in their oncology portfolio. Read more → Novo Nordisk’s $5.2 billion acquisition of Akero Therapeutics is set to boost their metabolic disease treatment offerings. Read more → Regulatory and Approvals Arrowhead’s Redemplo received FDA approval, marking a significant advancement in gene therapy.…